REPCF Financials 07/16/2014 19:15:04 RepliCel Lif

REPCF Financials 07/16/2014 19:15:04
RepliCel Life Sciences Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 3,878 - - -
Cost of Revenue - - - -
Gross Profit 3,878 - - -
Operating Expenses
Research and Development 1,470 1,070 1,001 554
Sales, General and Admin. 2,047 3,424 2,665 1,880
Non-Recurring Items - - - 118
Other - - - 7
Operating Income 361 (4,493) (3,666) (2,559)
Income From Continuing Operations
Add'l Income/Expense Items - 1,116 20 -
Earnings Before Interest and Tax 361 (3,378) (3,647) (2,559)
Interest Expense - - - -
Earnings Before Tax 361 (3,378) (3,647) (2,559)
Income Tax 388 - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (27) (3,378) (3,647) (2,559)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (27) (3,378) (3,647) (2,559)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (27) (3,378) (3,647) (2,559)